Glucan-Based Macrophage Stimulators
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Sepsis and sepsis syndrome are significant causes of morbidity and mortality in critically ill surgical patients. Despite technological and therapeutic advances in critical care, sepsis continues to be a pivotal factor in 20 to 50% of deaths in surgical intensive care units. It is clear that alternative approaches to the prevention and/or treatment of sepsis must be found.
Preclinical data indicate that macrophage activation with (1 →3)-β-D-glucans will ameliorate sequelae associated with Gram-negative septicaemia. We and others have translated these preclinical observations to the clinical setting and have shown that macrophage activation with (1→3)-β-D-glucans will significantly reduce septic morbidity and mortality in trauma and/or high-risk surgical patients. The precise mechanism(s) by which (1→3)-β-D-glucans prevent or ameliorate infections have not been fully elucidated. However, recent data suggest the anti-infective efficacy of (1→3)-β-D-glucans is attributable, in part, to macrophage activation induced by binding of (1→3)-β-D-glucan to a specific receptor followed by modulation of macrophage pro-inflammatory cytokine expression.
This article reviews the anti-infective potential of (1→3)-β-D-glucans in the prevention of sepsis and septic sequelae.
- Glucan-Based Macrophage Stimulators
Volume 5, Issue 5 , pp 392-399
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors